Novel Cytokine Peptide-based And Virus-like Particle Vaccines For Treatment Of Inflammatory Bowel Disease | 3300
Journal of Gastrointestinal & Digestive System
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
In Crohn?s disease, the tissue damage likely results from exaggerated Th1, IL-23/IL-17 pathway and IL-18 immune
responses to antigens of the gut microflora. Blocking these cytokines with monoclonal antibodies (mAb) has been used in the
treatment of the disease. However, the short half-life of the mAb and the development of antibodies to the infused mAb limit the
use of this reagent.
To develop cytokine peptide-based and virus-like particle vaccines which induce long-lasting antibodies to the p40 subunit
(shared by IL-12 & IL-23) or IL-18 or TGFβ1 and evaluate their effects in animal models.
The vaccine was constructed by inserting a small peptide, derived from the receptor binding site of the target cytokine,
into a carrier, hepatitis B core antigen, via gene recombination methods. Recombinant vaccines were expressed using
purified appropriately. Chronic colitis was induced by weekly intrarectal administration of trinitrobenzene sulfonic acid eight
times. At week 2, mice received three subcutaneous injections of vaccine or carrier or saline in a two-week interval.
The vaccine that was presented as virus-like particles induced strong and long-lasting antibody responses against the
target cytokine without the use of an adjuvant. Administration of a vaccine against the p40 subunit or IL-18 or TGFβ1 significantly
down-regulated intestinal inflammation and fibrosis in mice with chronic colitis, as shown by the decrease in body weight loss,
intestinal inflammation (H&E staining), amounts of soluble collagen and pro-inflammatory cytokines in colon tissue.
Cytokine vaccines may provide a potential therapeutic approach for the long-term treatment of inflammatory bowel
Zhikang Peng received an M.D. in 1968 from Fudan University School of Medicine and then worked as a clinician. After training as a post-doctoral
fellow in Johns Hopkins University and the University of Manitoba, in 1992 Dr. Peng became a faculty member in the University of Manitoba. Her
current research interests are in the development of novel immunotherapies for treatment of inflammatory bowel disease and asthma. She is
currently a Professor in the Dept. of Pediatrics and the Dept. of Immunology of the University of Manitoba and has published more than 70 papers
in peer-reviewed journals.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals